<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-15" updated="2019-12-02">
  <drugbank-id primary="true">DB08747</drugbank-id>
  <name>(11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one</name>
  <description/>
  <cas-number/>
  <unii/>
  <average-mass>445.338</average-mass>
  <monoisotopic-mass>444.100747994</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).</description>
    <direct-parent>Benzodiazepines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Benzodiazepines</class>
    <subclass/>
    <alternative-parent>1,4-diazepines</alternative-parent>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>1-hydroxy-4-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Acetamides</alternative-parent>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Cyclohexenones</alternative-parent>
    <alternative-parent>Dichlorobenzenes</alternative-parent>
    <alternative-parent>Enamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary alkylarylamines</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>1,3-dichlorobenzene</substituent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>1-hydroxy-4-unsubstituted benzenoid</substituent>
    <substituent>Acetamide</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzodiazepine</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Cyclohexenone</substituent>
    <substituent>Enamine</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Para-diazepine</substituent>
    <substituent>Secondary aliphatic/aromatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>3gol</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.12</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.33e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(10R)-9-acetyl-10-(2,4-dichlorophenyl)-4-hydroxy-14,14-dimethyl-2,9-diazatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7-tetraen-12-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(10R)-9-acetyl-10-(2,4-dichlorophenyl)-4-hydroxy-14,14-dimethyl-2,9-diazatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7-tetraen-12-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>445.338</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>444.100747994</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@]1(N(C(C)=O)C2=CC=CC(O)=C2NC2=C1C(=O)CC(C)(C)C2)C1=C(Cl)C=C(Cl)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C23H22Cl2N2O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C23H22Cl2N2O3/c1-12(28)27-17-5-4-6-18(29)21(17)26-16-10-23(2,3)11-19(30)20(16)22(27)14-8-7-13(24)9-15(14)25/h4-9,22,26,29H,10-11H2,1-3H3/t22-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>JJTPPGUNMJMPLY-QFIPXVFZSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>69.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>120.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>44.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.58</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>44574544</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99445218</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>24692535</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>XND</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL466269</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004389</id>
      <name>Genome polyprotein</name>
      <organism/>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O92972" source="Swiss-Prot">
        <name>Genome polyprotein</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Host endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>169-189
359-379
726-746
758-778
783-803
814-834
882-902
929-949
1658-1678
1806-1826
1829-1849
1851-1871
1882-1902
2990-3010</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.17</theoretical-pi>
        <molecular-weight>326763.605</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="11116">HCV</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D10750</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>221607</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O92972</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>POLG_HCVJ4</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.22.-</synonym>
          <synonym>p23</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021384|Genome polyprotein
MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKASERSQPRG
RRQPIPKARRPEGRAWAQPGYPWPLYGNEGLGWAGWLLSPRGSRPSWGPTDPRRRSRNLG
KVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGVRVLEDGVNYATGNLPGCSFSIFLLA
LLSCLTIPASAYEVRNVSGIYHVTNDCSNSSIVYEAADVIMHTPGCVPCVREGNSSRCWV
ALTPTLAARNASVPTTTIRRHVDLLVGTAAFCSAMYVGDLCGSIFLVSQLFTFSPRRHET
VQDCNCSIYPGHVSGHRMAWDMMMNWSPTTALVVSQLLRIPQAVVDMVAGAHWGVLAGLA
YYSMVGNWAKVLIVALLFAGVDGETHTTGRVAGHTTSGFTSLFSSGASQKIQLVNTNGSW
HINRTALNCNDSLQTGFFAALFYAHKFNSSGCPERMASCRPIDWFAQGWGPITYTKPNSS
DQRPYCWHYAPRPCGVVPASQVCGPVYCFTPSPVVVGTTDRSGVPTYSWGENETDVMLLN
NTRPPQGNWFGCTWMNSTGFTKTCGGPPCNIGGVGNRTLICPTDCFRKHPEATYTKCGSG
PWLTPRCLVDYPYRLWHYPCTLNFSIFKVRMYVGGVEHRLNAACNWTRGERCNLEDRDRS
ELSPLLLSTTEWQILPCAFTTLPALSTGLIHLHQNIVDVQYLYGVGSAFVSFAIKWEYIL
LLFLLLADARVCACLWMMLLIAQAEAALENLVVLNAASVAGAHGILSFLVFFCAAWYIKG
RLAPGAAYAFYGVWPLLLLLLALPPRAYALDREMAASCGGAVLVGLVFLTLSPYYKVFLT
RLIWWLQYFITRAEAHMQVWVPPLNVRGGRDAIILLTCAVHPELIFDITKLLLAILGPLM
VLQAGITRVPYFVRAQGLIRACMLVRKVAGGHYVQMAFMKLGALTGTYVYNHLTPLRDWA
HAGLRDLAVAVEPVVFSAMETKVITWGADTAACGDIILGLPVSARRGKEIFLGPADSLEG
QGWRLLAPITAYSQQTRGVLGCIITSLTGRDKNQVEGEVQVVSTATQSFLATCINGVCWT
VYHGAGSKTLAGPKGPITQMYTNVDLDLVGWQAPPGARSMTPCSCGSSDLYLVTRHADVI
PVRRRGDSRGSLLSPRPVSYLKGSSGGPLLCPSGHVVGVFRAAVCTRGVAKAVDFIPVES
METTMRSPVFTDNSSPPAVPQTFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAA
TLGFGAYMSKAHGIDPNIRTGVRTITTGGSITYSTYGKFLADGGCSGGAYDIIICDECHS
TDSTTILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIEEIGLSNNGEIPFYGKAI
PIEAIKGGRHLIFCHSKKKCDELAAKLTGLGLNAVAYYRGLDVSVIPPIGDVVVVATDAL
MTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTVPQDAVSRSQRRGRTGRGRSGIYR
FVTPGERPSGMFDSSVLCECYDAGCAWYELTPAETSVRLRAYLNTPGLPVCQDHLEFWES
VFTGLTHIDAHFLSQTKQAGDNFPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHG
PTPLLYRLGAVQNEVILTHPITKYIMACMSADLEVVTSTWVLVGGVLAALAAYCLTTGSV
VIVGRIILSGKPAVVPDREVLYQEFDEMEECASQLPYIEQGMQLAEQFKQKALGLLQTAT
KQAEAAAPVVESKWRALETFWAKHMWNFISGIQYLAGLSTLPGNPAIASLMAFTASITSP
LTTQNTLLFNILGGWVAAQLAPPSAASAFVGAGIAGAAVGSIGLGKVLVDILAGYGAGVA
GALVAFKVMSGEVPSTEDLVNLLPAILSPGALVVGVVCAAILRRHVGPGEGAVQWMNRLI
AFASRGNHVSPTHYVPESDAAARVTQILSSLTITQLLKRLHQWINEDCSTPCSGSWLRDV
WDWICTVLTDFKTWLQSKLLPRLPGVPFLSCQRGYKGVWRGDGIMQTTCPCGAQIAGHVK
NGSMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVEVTRVGDFH
YVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPACKPLLREDVTFQVGLNQYLVGSQL
PCEPEPDVTVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLKATCTTHHD
SPDADLIEANLLWRQEMGGNITRVESENKVVILDSFEPLHAEGDEREISVAAEILRKSRK
FPSALPIWARPDYNPPLLESWKDPDYVPPVVHGCPLPPTKAPPIPPPRRKRTVVLTESNV
SSALAELATKTFGSSGSSAVDSGTATALPDLASDDGDKGSDVESYSSMPPLEGEPGDPDL
SDGSWSTVSEEASEDVVCCSMSYTWTGALITPCAAEESKLPINPLSNSLLRHHNMVYATT
SRSASLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKAKLLSIEEACKLTPPHSAKSKF
GYGAKDVRNLSSRAVNHIRSVWEDLLEDTETPIDTTIMAKSEVFCVQPEKGGRKPARLIV
FPDLGVRVCEKMALYDVVSTLPQAVMGSSYGFQYSPKQRVEFLVNTWKSKKCPMGFSYDT
RCFDSTVTESDIRVEESIYQCCDLAPEARQAIRSLTERLYIGGPLTNSKGQNCGYRRCRA
SGVLTTSCGNTLTCYLKATAACRAAKLQDCTMLVNGDDLVVICESAGTQEDAAALRAFTE
AMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDASGKRVYYLTRDPTTPLARAAWETAR
HTPINSWLGNIIMYAPTLWARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQ
IIERLHGLSAFTLHSYSPGEINRVASCLRKLGVPPLRTWRHRARSVRAKLLSQGGRAATC
GRYLFNWAVRTKLKLTPIPAASQLDLSGWFVAGYSGGDIYHSLSRARPRWFPLCLLLLSV
GVGIYLLPNR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0008332|9033 bp
ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCACAG
GACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGCGCAGG
GGCCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAACCTCGTGGA
AGGCGACAACCTATCCCAAAGGCTCGCCAACCCGAGGGCAGGGCCTGGGCTCAGCCCGGG
TACCCTTGGCCCCTCTATGGCAATGAGGGCTTGGGGTGGGCAGGATGGCTCCTGTCACCC
CGCGGCTCCCGGCCTAGTTGGGGCCCCACGGACCCCCGGCGTAGGTCGCGTAACTTGGGT
AAGGTCATCGATACCCTTACATGCGGCTTCGCCGATCTCATGGGGTACATTCCGCTCGTC
GGCGCCCCCCTAGGGGGCGCTGCCAGGGCCTTGGCACACGGTGTCCGGGTTCTGGAGGAC
GGCGTGAACTATGCAACAGGGAACTTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCT
CTGCTGTCCTGTTTGACCATCCCAGCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGATA
TACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTATGAGGCAGCGGACGTGATC
ATGCATACTCCCGGGTGCGTGCCCTGTGTTCGGGAGGGCAACAGCTCCCGTTGCTGGGTA
GCGCTCACTCCCACGCTCGCGGCCAGAGATGCCAGCGTCCCCACTACGACAATACGACGC
CACGTCGACTTGCTCGTTGGGACGGCTGCTTTCTGCTCCGCTATGTACGTGGGGGATCTC
TGCGGATCTATTTTCCTCGTCTCCCAGCTGTTCACCTTCTCGCCTCGCCGGCATGAGACA
GTGCAGGACTGCAACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGG
GATATGATGATGAACTGGTCACCTACAACAGCCCTAGTGGTGTCGCAGTTGCTCCGGATC
CCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCACTGGGGAGTCCTGGCGGGCCTTGCC
TACTATTCCATGGTAGGGAACTGGGCTAAGGTTCTGATTGTGGCGCTACTCTTTGCCGGC
GTTGACGGGGCGACCTACACGTCGGGGGGGGTGGCCGGCCGCACCACCTCCGGGTTCACG
TCCCTCTTCTCATCTGGGGCGTCTCAGAAAATCCAGCTTGTGAATACCAACGGCAGCTGG
CACATCAACAGGACTGCCCTAAATTGCAATGACTCCCTCCACACTGGGTTCCTTGCCGCG
CTGTTCTACACACACAAGTTCAACTCGTCCGGGTGCCCGGAGCGCATGGCCAGCTGCCGC
CCCATTGACGGGTTCGCCCAGGGATGGGGCCCCATCACCTATACTGAGCCTAACAGCCCG
GATCAGAGGCCTTATTGCTGGCATTACGCGCCTCGACCGTGTGGTATCGTACCCGCGTCG
CAGGTGTGTGGTCCAGTGTATTGTTTCACCCCAAGCCCTGTTGTGGTGGGGACCACCGAT
CGTTCCGGTGTCCCTACGTATAGCTGGGGGGAGAATGAGACAGACGTGATGCTCCTCAAC
AACACGCGTCCGCCACAAGGCAACTGGTTCGGCTGTACATGGATGAATAGTACTGGGTTC
ACTAAGACGTGCGGAGGCCCCCCGTGTAACATCGGGGGGGTCGGTAACCGCACCTTGATC
TGCCCCACGGACTGCTTCCGGAAGCACCCCGAGGCTACTTACACAAAATGTGGCTCGGGG
CCCTGGTTGACACCTAGGTGCCTAGTAGACTACCCATACAGGCTCTGGCACTACCCCTGC
ACTCTCAATTTTTCCATCTTTAAGGTTAGGATGTATGTGGGGGGCGTGGAGCACAGGCTC
AATGCCGCATGCAATTGGACTCGAGGAGAGCGCTGTAACTTGGAGGACAGGGATAGGTCA
GAACTCAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTGCCTTCACC
ACCCTACCGGCTTTATCCACTGGTTTGATCCATCTCCATCAGAACATCGTGGACGTGCAA
TACCTGTACGGTGTAGGGTCAGCGTTTGTCTCCTTTGCAATCAAATGGGAGTACATCCTG
TTGCTTTTCCTTCTCCTGGCAGACGCGCGCGTGTGTGCCTGCTTGTGGATGATGCTGCTG
ATAGCCCAGGCTGAGGCCGCCTTAGAGAACTTGGTGGTCCTCAATGCGGCGTCCGTGGCC
GGAGCGCATGGTATTCTCTCCTTTCTTGTGTTCTTCTGCGCCGCCTGGTACATTAAGGGC
AGGCTGGCTCCTGGGGCGGCGTATGCTTTTTATGGCGTATGGCCGCTGCTCCTGCTCCTA
CTGGCGTTACCACCACGAGCTTACGCCTTGGACCGGGAGATGGCTGCATCGTGCGGGGGT
GCGGTTCTTGTAGGTCTGGTATTCTTGACCTTGTCACCATACTACAAAGTGTTTCTCACT
AGGCTCATATGGTGGTTACAATACTTTATCACCAGAGCCGAGGCGCACATGCAAGTGTGG
GTCCCCCCCCTCAACGTTCGGGGAGGCCGCGATGCCATCATCCTCCTCACGTGTGCGGTT
CATCCAGAGTTAATTTTTGACATCACCAAACTCCTGCTCGCCATACTCGGCCCGCTCATG
GTGCTCCAGGCTGGCATAACGAGAGTGCCGTACTTCGTGCGCGCTCAAGGGCTCATTCGT
GCATGCATGTTAGTGCGGAAAGTCGCCGGGGGTCATTATGTCCAAATGGCCTTCATGAAG
CTGGGCGCGCTGACAGGTACGTACGTTTATAACCATCTTACCCCACTGCGGGACTGGGCC
CACGCGGGCCTACGAGACCTTGCGGTGGCGGTAGAGCCCGTCGTCTTCTCCGCCATGGAG
ACCAAGGTCATCACCTGGGGAGCAGACACCGCAGCATGTGGAGACATCATCTTGGGCCTA
CCCGTCTCCGCCCGAAGGGGGAAGGAGATATTTTTGGGACCGGCTGATAGTCTCGAAGGG
CAAGGGTGGCGACTCCTTGCGCCCATCACGGCCTACTCCCAACAAACGCGGGGCGTACTT
GGTTGCATCATCACTAGCCTCACAGGCCGGGACAAGAACCAGGTCGAGGGGGAGGTTCAA
GTGGTTTCTACCGCAACACAATCTTTCCTGGCGACCTGCATCAACGGCGTGTGCTGGACT
GTCTACCATGGCGCTGGCTCGAAGACCCTAGCCGGTCCAAAAGGTCCAATCACCCAAATG
TACACCAATGTAGACCTGGACCTCGTCGGCTGGCAGGCGCCCCCCGGGGCGCGCTCCATG
ACACCATGCAGCTGTGGCAGCTCGGACCTTTACTTGGTCACGAGACATGCTGATGTCATT
CCGGTGCGCCGGCGAGGCGACAGCAGGGGAAGTCTACTCTCCCCCAGGCCCGTCTCCTAC
CTGAAGGGCTCCTCGGGTGGTCCATTGCTTTGCCCTTCGGGGCACGTCGTGGGCGTCTTC
CGGGCTGCTGTGTGCACCCGGGGGGTCGCGAAGGCGGTGGACTTCATACCCGTTGAGTCT
ATGGAAACTACCATGCGGTCTCCGGTCTTCACAGACAACTCATCCCCCCCGGCTGTACCG
CAGACATTCCAAGTGGCACATCTGCACGCTCCTACTGGCAGCGGCAAGAGCACTAAAGTG
CCGGCTGCGTATGCAGCCCAAGGGTACAAGGTGCTCGTCCTGAACCCGTCCGTTGCCGCC
ACCTTAGGGTTTGGGGCGTATATGTCCAAGGCACACGGTATCGACCCTAACATCAGAACT
GGGGTAAGGACCATTACCACGGGCGGCTCCATTACGTACTCCACCTATGGCAAGTTCCTT
GCCGACGGTGGCTGCTCCGGGGGCGCCTATGACATCATAATATGTGATGAGTGCCACTCA
ACTGACTCGACTACCATCTTGGGCATCGGCACAGTCCTGGACCAAGCGGAGACGGCTGGA
GCGCGGCTTGTCGTGCTCGCCACCGCTACACCTCCGGGATCGGTTACCGTGCCACACCCC
AATATCGAGGAAATAGGCCTGTCCAACAATGGAGAGATCCCCTTCTATGGCAAAGCCATC
CCCATTGAGGCCATCAAGGGGGGGAGGCATCTCATTTTCTGCCATTCCAAGAAGAAATGT
GACGAGCTCGCCGCAAAGCTGACAGGCCTCGGACTGAATGCTGTAGCATATTACCGGGGC
CTTGATGTGTCCGTCATACCGCCTATCGGAGACGTCGTTGTCGTGGCAACAGACGCTCTA
ATGACGGGTTTCACCGGCGATTTTGACTCAGTGATCGACTGCAACACATGTGTCACCCAG
ACAGTCGACTTCAGCTTGGATCCCACCTTCACCATTGAGACGACGACCGTGCCCCAAGAC
GCGGTGTCGCGCTCGCAACGGCGAGGTAGAACTGGCAGGGGTAGGAGTGGCATCTACAGG
TTTGTGACTCCAGGAGAACGGCCCTCGGGCATGTTCGATTCTTCGGTCCTGTGTGAGTGC
TATGACGCGGGCTGTGCTTGGTATGAGCTCACGCCCGCTGAGACCTCGGTTAGGTTGCGG
GCTTACCTAAATACACCAGGGTTGCCCGTCTGCCAGGACCATCTGGAGTTCTGGGAGAGC
GTCTTCACAGGCCTCACCCACATAGATGCCCACTTCCTGTCCCAGACTAAACAGGCAGGA
GACAACTTTCCTTACCTGGTGGCATATCAAGCTACAGTATGCGCCAGGGCTCAAGCTCCA
CCTCCATCGTGGGACCAAATGTGGAAGTGTCTCATACGGCTGAAACCTACACTGCACGGG
CCAACACCCCTGCTGTATAGGCTAGGAGCCGTCCAAAATGAGGTCATCCTCACACACCCC
ATAACTAAATACATCATGGCATGCATGTCGGCTGACCTGGAGGTCGTCACTAGCACCTGG
GTGCTGGTAGGCGGAGTCCTTGCAGCTTTGGCCGCATATTGCCTGACGACAGGCAGTGTG
GTCATTGTGGGCAGGATCATCTTGTCCGGGAAGCCAGCTGTCGTTCCCGACAGGGAAGTC
CTCTACCAGGAGTTCGATGAGATGGAAGAGTGTGCCTCACAACTTCCTTACATCGAGCAG
GGAATGCAGCTCGCCGAGCAATTTAAGCAAAAGGCGCTCGGGTTGTTGCAAACGGCCACC
AAGCAAGCGGAGGCTGCTGCTCCCGTGGTGGAGTCCAAGTGGCGAGCCCTTGAGACCTTC
TGGGCGAAGCACATGTGGAATTTCATCAGCGGGATACAGTACCTAGCAGGCTTATCCACT
CTGCCTGGGAACCCCGCGATAGCATCATTGATGGCATTTACAGCTTCTATCACTAGCCCG
CTCACCACCCAAAACACCCTCCTGTTTAACATCTTGGGGGGATGGGTGGCTGCCCAACTC
GCTCCTCCCAGCGCTGCGTCAGCTTTCGTGGGCGCCGGCATCGCCGGAGCGGCTGTTGGC
AGCATAGGCCTTGGGAAGGTGCTCGTGGACATCTTGGCGGGCTATGGGGCAGGGGTAGCC
GGCGCACTCGTGGCCTTTAAGGTCATGAGCGGCGAGGTGCCCTCCACCGAGGACCTGGTC
AACTTACTCCCTGCCATCCTCTCTCCTGGTGCCCTGGTCGTCGGGGTCGTGTGCGCAGCA
ATACTGCGTCGGCACGTGGGCCCGGGAGAGGGGGCTGTGCAGTGGATGAACCGGCTGATA
GCGTTCGCTTCGCGGGGTAACCACGTCTCCCCCACGCACTATGTGCCTGAGAGCGACGCT
GCAGCACGTGTCACTCAGATCCTCTCTAGCCTTACCATCACTCAACTGCTGAAGCGGCTT
CACCAGTGGATTAATGAGGACTGCTCTACGCCATGCTCCGGCTCGTGGCTAAGGGATGTT
TGGGATTGGATATGCACGGTGTTGACTGACTTCAAGACCTGGCTCCAGTCCAAGCTCCTG
CCGCGGTTACCGGGAGTCCCTTTCCTGTCATGCCAACGCGGGTACAAGGGAGTCTGGCGG
GGGGACGGCATCATGCAAACCACCTGCCCATGTGGAGCACAGATCGCCGGACATGTCAAA
AACGGTTCCATGAGGATCGTAGGGCCTAGAACCTGCAGCAACACGTGGCACGGAACGTTC
CCCATCAACGCATACACCACGGGACCCTGCACACCCTCCCCGGCGCCCAACTATTCCAGG
GCGCTATGGCGGGTGGCTGCTGAGGAGTACGTGGAGGTTACGCGTGTGGGAGATTTCCAC
TACGTGACGGGCATGACCACTGACAACGTAAAGTGCCCATGCCAGGTTCCGGCCCCCGAA
TTCTTCACGGAGGTGGATGGAGTGCGGTTGCACAGGTACGCTCCGGCGTGCAAACCTCTC
CTACGGGAGGACGTCACGTTCCAGGTCGGGCTCAACCAATACTTGGTCGGGTCGCAGCTC
CCATGCGAGCCCGAACCGGACGTAACAGTGCTTACTTCCATGCTCACCGATCCCTCCCAC
ATTACAGCAGAGACGGCTAAGCGTAGGCTGGCTAGAGGGTCCCCCCCCTCTTTAGCCAGC
TCATCAGCTAGCCAGTTGTCTGCGCCTTCTTTGAAGGCGACATGCACTACCCACCATGAC
TCCCCGGACGCTGACCTCATCGAGGCCAACCTCTTGTGGCGGCAGGAGATGGGCGGAAAC
ATCACTCGCGTGGAGTCAGAGAATAAGGTAGTAATTCTGGACTCTTTCGAACCGCTTCAC
GCGGAGGGGGATGAGAGGGAGATATCCGTCGCGGCGGAGATCCTGCGAAAATCCAGGAAG
TTCCCCTCAGCGTTGCCCATATGGGCACGCCCGGACTACAATCCTCCACTGCTAGAGTCC
TGGAAGGACCCGGACTACGTCCCTCCGGTGGTACACGGATGCCCATTGCCACCTACCAAG
GCTCCTCCAATACCACCTCCACGGAGAAAGAGGACGGTTGTCCTGACAGAATCCAATGTG
TCTTCTGCCTTGGCGGAGCTCGCCACTAAGACCTTCGGTAGCTCCGGATCGTCGGCCGTT
GATAGCGGCACGGCGACCGCCCTTCCTGACCTGGCCTCCGACGACGGTGACAAAGGGTCC
GACGTTGAGTCGTACTCCTCCATGCCCCCCCTTGAAGGGGAGCCGGGGGACCCCGATCTC
AGCGACGGGTCTTGGTCTACCGTGAGTGAGGAGGCTAGTGAGGACGTCGTCTGCTGCTCA
ATGTCCTATACGTGGACAGGCGCCCTGATCACGCCATGCGCTGCGGAGGAAAGTAAGCTG
CCCATCAACCCGTTGAGCAACTCTTTGCTGCGTCACCACAACATGGTCTACGCCACAACA
TCCCGCAGCGCAAGCCTCCGGCAGAAGAAGGTCACCTTTGACAGATTGCAAGTCCTGGAT
GACCATTACCGGGACGTGCTCAAGGAGATGAAGGCGAAGGCGTCCACAGTTAAGGCTAAG
CTTCTATCTATAGAGGAGGCCTGCAAGCTGACGCCCCCACATTCGGCCAAATCCAAATTT
GGCTATGGGGCAAAGGACGTCCGGAACCTATCCAGCAGGGCCGTTAACCACATCCGCTCC
GTGTGGGAGGACTTGCTGGAAGACACTGAAACACCAATTGACACCACCATCATGGCAAAA
AGTGAGGTTTTCTGCGTCCAACCAGAGAAGGGAGGCCGCAAGCCAGCTCGCCTTATCGTA
TTCCCAGACCTGGGAGTTCGTGTATGCGAGAAGATGGCCCTTTACGACGTGGTCTCCACC
CTTCCTCAGGCCGTGATGGGCTCCTCATACGGATTTCAATACTCCCCCAAGCAGCGGGTC
GAGTTCCTGGTGAATACCTGGAAATCAAAGAAATGCCCTATGGGCTTCTCATATGACACC
CGCTGTTTTGACTCAACGGTCACTGAGAGTGACATTCGTGTTGAGGAGTCAATTTACCAA
TGTTGTGACTTGGCCCCCGAGGCCAGACAGGCCATAAGGTCGCTCACGGAGCGGCTTTAC
ATCGGGGGTCCCCTGACTAACTCAAAAGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCA
AGTGGCGTGCTGACGACTAGCTGCGGTAATACCCTCACATGTTACTTGAAGGCCACTGCG
GCCTGTCGAGCTGCAAAGCTCCAGGACTGCACGATGCTCGTGAACGGAGACGACCTTGTC
GTTATCTGTGAAAGCGCGGGAACCCAGGAGGATGCGGCGGCCCTACGAGCCTTCACGGAG
GCTATGACTAGGTACTCCGCCCCCCCCGGGGATCCGCCCCAACCAGAATACGACCTGGAG
CTGATAACATCATGTTCCTCCAATGTGTCAGTCGCGCACGATGCATCTGGCAAAAGGGTA
TACTACCTCACCCGTGACCCCACCACCCCCCTTGCACGGGCTGCGTGGGAGACAGCTAGA
CACACTCCAATCAACTCTTGGCTAGGCAATATCATCATGTATGCGCCCACCCTATGGGCA
AGGATGATTCTGATGACTCACTTTTTCTCCATCCTTCTAGCTCAAGAGCAACTTGAAAAA
GCCCTGGATTGTCAGATCTACGGGGCCTGCTACTCCATTGAGCCACTTGACCTACCTCAG
ATCATTGAACGACTCCATGGTCTTAGCGCATTTACACTCCACAGTTACTCTCCAGGTGAG
ATCAATAGGGTGGCTTCATGCCTCAGGAAACTTGGGGTACCACCCTTGCGAACCTGGAGA
CATCGGGCCAGAAGTGTCCGCGCTAAGCTACTGTCCCAGGGGGGGAGGGCCGCCACTTGT
GGCAGATACCTCTTTAACTGGGCAGTAAGGACCAAGCTTAAACTCACTCCAATCCCGGCT
GCGTCCCAGCTGGACTTGTCCGGCTGGTTCGTCGCTGGTTACAGCGGGGGAGACATATAT
CACAGCCTGTCTCGTGCCCGACCCCGCTGGTTTCCGTTGTGCCTACTCCTACTTTTTGTA
GGGGTAGGCATTTACCTGCTCCCCAACCGATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01543</identifier>
            <name>HCV_capsid</name>
          </pfam>
          <pfam>
            <identifier>PF01542</identifier>
            <name>HCV_core</name>
          </pfam>
          <pfam>
            <identifier>PF01539</identifier>
            <name>HCV_env</name>
          </pfam>
          <pfam>
            <identifier>PF01560</identifier>
            <name>HCV_NS1</name>
          </pfam>
          <pfam>
            <identifier>PF01538</identifier>
            <name>HCV_NS2</name>
          </pfam>
          <pfam>
            <identifier>PF01006</identifier>
            <name>HCV_NS4a</name>
          </pfam>
          <pfam>
            <identifier>PF01001</identifier>
            <name>HCV_NS4b</name>
          </pfam>
          <pfam>
            <identifier>PF01506</identifier>
            <name>HCV_NS5a</name>
          </pfam>
          <pfam>
            <identifier>PF08300</identifier>
            <name>HCV_NS5a_1a</name>
          </pfam>
          <pfam>
            <identifier>PF08301</identifier>
            <name>HCV_NS5a_1b</name>
          </pfam>
          <pfam>
            <identifier>PF02907</identifier>
            <name>Peptidase_S29</name>
          </pfam>
          <pfam>
            <identifier>PF00998</identifier>
            <name>RdRP_3</name>
          </pfam>
          <pfam>
            <identifier>PF07652</identifier>
            <name>Flavi_DEAD</name>
          </pfam>
          <pfam>
            <identifier>PF12941</identifier>
            <name>HCV_NS5a_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell lipid particle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral to membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral nucleocapsid</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>14-3-3 protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP-dependent helicase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase C binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA-directed RNA polymerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>SMAD binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural molecule activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>clathrin-mediated endocytosis of virus by host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fusion of virus membrane with host endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>induction by virus of host autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modulation by virus of host G1/S transition checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of SMAD protein complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transforming growth factor beta receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pore formation by virus in membrane of host cell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host MAVS activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host STAT1 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host TRAF activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suppression by virus of host type I interferon-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transformation of host cell by virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral RNA genome replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>virion attachment to host cell</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>